- Home
- CRT vs IKNA Comparison
CRT vs IKNA Comparison
Compare CRT & IKNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CRT
- IKNA
- Stock Information
- Founded
- CRT 1991
- IKNA 2016
- Country
- CRT United States
- IKNA United States
- Employees
- CRT N/A
- IKNA N/A
- Industry
- CRT Oil & Gas Production
- IKNA Biotechnology: Pharmaceutical Preparations
- Sector
- CRT Energy
- IKNA Health Care
- Exchange
- CRT Nasdaq
- IKNA Nasdaq
- Market Cap
- CRT 65.1M
- IKNA 61.8M
- IPO Year
- CRT 1992
- IKNA 2021
- Fundamental
- Price
- CRT $9.78
- IKNA $1.35
- Analyst Decision
- CRT
- IKNA Strong Buy
- Analyst Count
- CRT 0
- IKNA 1
- Target Price
- CRT N/A
- IKNA $4.00
- AVG Volume (30 Days)
- CRT 24.7K
- IKNA 79.7K
- Earning Date
- CRT 01-01-0001
- IKNA 08-07-2025
- Dividend Yield
- CRT 9.01%
- IKNA N/A
- EPS Growth
- CRT N/A
- IKNA N/A
- EPS
- CRT 0.99
- IKNA N/A
- Revenue
- CRT $6,834,116.00
- IKNA N/A
- Revenue This Year
- CRT N/A
- IKNA N/A
- Revenue Next Year
- CRT N/A
- IKNA N/A
- P/E Ratio
- CRT $9.89
- IKNA N/A
- Revenue Growth
- CRT N/A
- IKNA N/A
- 52 Week Low
- CRT $8.88
- IKNA $0.97
- 52 Week High
- CRT $13.31
- IKNA $1.94
- Technical
- Relative Strength Index (RSI)
- CRT 43.47
- IKNA 53.36
- Support Level
- CRT $9.66
- IKNA $1.31
- Resistance Level
- CRT $9.88
- IKNA $1.38
- Average True Range (ATR)
- CRT 0.17
- IKNA 0.06
- MACD
- CRT 0.00
- IKNA -0.01
- Stochastic Oscillator
- CRT 16.44
- IKNA 15.79
About CRT Cross Timbers Royalty Trust
Cross Timbers Royalty Trust is a United States-based trust. The net profits interests are derived from producing royalty, overriding royalty interests, and working interest properties. The underlying properties of the trust include producing properties in Texas, Oklahoma, and New Mexico.
About IKNA Ikena Oncology Inc.
Ikena Oncology Inc is a targeted oncology company developing precision therapies for patients in need that target nodes of cancer growth, spread, and therapeutic resistance in the Hippo and RAS onco-signaling network. Its targeted oncology product candidate, IK-930, is an oral small-molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, a transcription factor in the Hippo signaling pathway, a known oncogenic pathway that also drives resistance to multiple targeted and chemotherapies. Its other product candidates are IK-175 and IK-595.